Latest Breaking News On - நோய் தீவிரம் - Page 1 : comparemela.com

New Dupixent® (dupilumab) Data in Patients as Young as Six Years Old With Moderate-to-Severe Atopic Dermatitis to Be Presented at WCPD and EADV

New Dupixent® (dupilumab) Data in Patients as Young as Six Years Old With Moderate-to-Severe Atopic Dermatitis to Be Presented at WCPD and EADV
prnewswire.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from prnewswire.com Daily Mail and Mail on Sunday newspapers.

France generalJonathan silverbergYoko kataokaEric simpsonKen igawaGeorged yancopoulosRegeneron velocimmuneElaine siegfriedStephan weidingerAmy pallerDupilumab monotherapyAlisa beckAndreas wollenbergMichael wechslerCarlos ferrVenereology congress

Regeneron Pharmaceuticals : New Dupixent® (dupilumab) Data in Patients as Young as Six Years Old With Moderate-to-Severe Atopic Dermatitis to Be Presented at WCPD and EADV

Regeneron Pharmaceuticals : New Dupixent® (dupilumab) Data in Patients as Young as Six Years Old With Moderate-to-Severe Atopic Dermatitis to Be Presented at WCPD and EADV
marketscreener.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from marketscreener.com Daily Mail and Mail on Sunday newspapers.

Chronic Sinusitis Prevalence in the US: Characterised by Vastly Untreated Population

Press release content from Business Wire. The AP news staff was not involved in its creation.

United statesSouth koreaSchindler endoskopie technologie gmbhAlthea deutschlandWolf gmbLaura woodAge group in millionOffice hours callRichard wolf corporationGlobal telemedicine incE st office hours callStryker corporationOlympus corporationMarket trajectoryLatin americaCompetitors featured

Heparin s COVID-19 Benefit Greatest in Moderately Ill Patients

Therapeutic levels of heparin can have widely varying effects on COVID-19 patients depending on the severity of their disease, according to a multiplatform clinical trial.

United statesLeo pharmaPatrickr lawlerPortola alexionDeepakl bhattJeffreys bergerMultifactorial adaptive platform trial for communityMaastricht universityMedscape coronavirus resource centerWomen hospital heart vascular centerCanadian institutes of health researchEuropean unionPeter munk cardiac centre at torontoBlood instituteNational heartCoronavirus resource

Frontiers | Emergence of Dengue 4 as Dominant Serotype During 2017 Outbreak in South India and Associated Cytokine Expression Profile

Dengue virus infection is prevalent in tropical and sub-tropical regions of the world, which is fatal if untreated symptomatically. Emergence of new genotype within serotypes led to enhanced severity. The objective of the study is to identify the molecular characteristics of the DENV circulated during 2017 outbreak in Tamil Nadu, India and, to investigate the role of inflammatory cytokines in different ‘serotypes’ and in ‘dengue severity’. A total of 135 suspected samples were tested for DENV infection using IgM, IgG and qPCR assay; where 76 samples were positive for DENV and analysed for twelve inflammatory cytokines using ELISA. Serotyping shows 14 DENV-1, 22 DENV-2, 7 DENV-3 and 33 DENV-4, where DENV-4 was predominant. Among seventy-six, forty-two isolates were successfully sequenced for C-prM region and grouped. A lineage shift was observed in DENV-4 genotype. Irrespective of serotypes, IFNγ was significantly elevated than control and in primary infection indicating its ro

United statesUnited kingdomNew delhiTamil naduSri lankaRepublic ofNorth westernCity ofAndaman and nicobar islandsSaudi arabiaGonzalez mateosFlores aguilarFlavivirus serocomplex crossVellore ceciliaCladec ceciliaLakshmana rao